

Mangum Regional 340B Summary YTD

Prescription Capture Criteria:

1. Brand name prescriptions only
2. Winners only model (i.e. profitable for both covered entity and the contract pharmacy)

Prescription Exclusion:

1. Generic medications
2. Medicaid patients
3. CII Prescriptions (cannot be refilled) and Orphan Drugs

340B Prescription Capture YTD

January	February	March	April	May	June
30	21	25	21	15	16

July	August	September	October	November	December
21					

340B Net Profit = Insurance Payment – (340B Purchase Price + Dispense Fee)

January	February	March	April	May	June
\$ 11,319.82	\$ 4,383.30	\$ 6,229.30	\$ 5,265.32	\$ 3,813.86	\$ 5,018.10

July	August	September	October	November	December
\$ 5,327.25					

Challenging trends with 340B Savings/Profits going forward:

1. Several medications have had an increase in the 340B acquisition cost effective July 1st, 2026 (340B prices are recalculated on a quarterly basis).
2. New CMS Maximum Fair Price (MFP) program allows CMS to negotiate directly with manufacturers on select Brand name prescriptions on a yearly basis. The net benefit lowers consumer prices of these medications but compresses the 340B profit margin of some commonly prescribed medications (e.g. Eliquis and Xarelto).
3. GLP1 Bridge program offers Medicare patients a fixed price of \$50 per month for select GLP1 medications prescribed for weight loss. The CMS reimbursement price to pharmacies varies depending on the medication prescribed. The 340B profit margin of Zepbound prescriptions is negative effective July 1st. As a result, Zepbound prescriptions will be carved out of the 340B program going forward (previously the covered entity made over \$200 per Zepbound prescription filled at the contract pharmacy).